Hereditary Hypophosphatemic Rickets with Hypercalciuria (HHRH) / NPHLOP1: A Patient Guide
At a Glance
HHRH and NPHLOP1 are inherited phosphate-wasting disorders in which the kidneys lose too much phosphate, driving high urine calcium despite usually normal blood calcium. This can cause kidney stones and rickets or osteomalacia; oral phosphate is usually the main treatment.
Hereditary Hypophosphatemic Rickets with Hypercalciuria (HHRH) and NPHLOP1 are rare genetic conditions that fundamentally change how your kidneys manage minerals. At the heart of these conditions is a “leak” in the kidney’s filtration system, specifically involving the SLC34A3 or SLC34A1 genes. These genes provide the blueprints for transporters that are supposed to recapture phosphate from your urine and put it back into your blood. When they fail, phosphate spills out of the body, triggering a complex biological chain reaction that affects both your bones and your kidneys [1][2].
This mineral leak creates a unique and often confusing situation for patients and doctors alike. In most bone-thinning diseases, the body is starved for vitamin D, but in HHRH, the body does the opposite: it senses the low phosphate and overproduces the active form of vitamin D (calcitriol) to compensate. While this surge is meant to help, it backfires by forcing the gut to absorb massive amounts of calcium. Because the body cannot use this extra calcium without enough phosphate, the kidneys must flush it out. This high urinary calcium (hypercalciuria) is what leads to the two main complications of the disease: painful kidney stones and soft, mineral-starved bones known as rickets in children or osteomalacia in adults [1][3]. Your blood calcium level usually remains normal while this occurs.
Because HHRH and NPHLOP1 behave differently than more common bone conditions, the diagnosis is frequently missed or delayed. A standard blood test may show low phosphate, but evaluating renal phosphate handling alongside high levels of calcium in the urine is necessary for an accurate diagnosis. Distinguishing this from other types of rickets is essential, as the treatment for HHRH is fundamentally different from what is typically prescribed for other bone disorders. While many bone conditions require active vitamin D supplements, taking active vitamin D analogs for confirmed HHRH can worsen hypercalciuria and nephrocalcinosis [1][4]. If you are currently taking active vitamin D, do not stop or change it without first contacting your prescriber or metabolic-bone team.
Living with HHRH or NPHLOP1 means focusing on a precise and consistent treatment plan. The standard of care is generally oral phosphate supplementation, which helps replace the phosphate lost by the kidney and signals the body to reduce its overproduction of active vitamin D. While this therapy is the foundation of care, it requires individualized, clinician-directed monitoring of your blood and urine to protect your kidney health. By understanding the unique biology of your condition and avoiding treatments that could cause harm, you can work with your medical team to strengthen your bones and safeguard your kidneys for the future [5][3].
In this guide
6 chapters
Understanding HHRH and NPHLOP1: When Stones and Bone Loss Meet
Learn how HHRH and NPHLOP1 cause phosphate wasting, kidney stones, and bone loss, including genetic testing, phosphate treatment, and long-term monitoring.
The Biology of Phosphate Wasting: How Your Genes Affect Your Kidneys
Learn how SLC34A3 and SLC34A1 mutations cause HHRH and NPHLOP1, leading to phosphate loss, high urine calcium, kidney stones, and bone problems in patients.
Symptoms of HHRH: From Childhood Rickets to Adult Kidney Stones
Learn how HHRH symptoms vary by age and gene changes, from childhood rickets and growth delay to adult kidney stones, osteomalacia, fractures, and bone pain.
Lab Tests & Reports: Decoding the Diagnostic Puzzle
Learn how to read HHRH and NPHLOP1 lab results, including phosphate, vitamin D, urine calcium, TmP/GFR, TRP, FGF23, PTH, and genetic testing for diagnosis.
The Standard of Care: Treating HHRH with Precision
Learn how HHRH, or hereditary hypophosphatemic rickets with hypercalciuria, is treated with oral phosphate, vitamin D safety, and kidney stone prevention.
Lifelong Protection: Monitoring Your Kidneys and Bones
Learn how hereditary hypophosphatemic rickets with hypercalciuria (HHRH) monitoring protects kidneys and bones with tests, imaging, and stone warning signs.
Common questions in this guide
What are HHRH and NPHLOP1?
Why can HHRH cause kidney stones when my blood calcium is normal?
Why is oral phosphate the usual treatment for HHRH or NPHLOP1?
Could active vitamin D make HHRH worse?
How is HHRH or NPHLOP1 diagnosed?
What symptoms can suggest HHRH or NPHLOP1?
Which specialists should manage HHRH or NPHLOP1?
Get notified when new evidence is published on nephrolithiasis/osteoporosis, hypophosphatemic.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
References
References (5)
- 1
Hereditary hypophosphatemic rickets with hypercalciuria: pathophysiology, clinical presentation, diagnosis and therapy.
Bergwitz C, Miyamoto KI
Pflugers Archiv : European journal of physiology 2019; (471(1)):149-163 doi:10.1007/s00424-018-2184-2.
PMID: 30109410 - 2
Renal phosphate handling and inherited disorders of phosphate reabsorption: an update.
Wagner CA, Rubio-Aliaga I, Hernando N
Pediatric nephrology (Berlin, Germany) 2019; (34(4)):549-559 doi:10.1007/s00467-017-3873-3.
PMID: 29275531 - 3
An update on clinical presentation and responses to therapy of patients with hereditary hypophosphatemic rickets with hypercalciuria (HHRH).
Zhu Z, Bo-Ran Ho B, Chen A, et al.
Kidney international 2024; (105(5)):1058-1076 doi:10.1016/j.kint.2024.01.031.
PMID: 38364990 - 4
Novel Variant of SLC34A3 in a Compound Heterozygous Brazilian Girl with Hereditary Hypophosphatemic Rickets with Hypercalciuria
Valadares LP, de Carvalho DR
Journal of clinical research in pediatric endocrinology 2025; (17(3)):326-331 doi:10.4274/jcrpe.galenos.2023.2023-5-2.
PMID: 37680384 - 5
Rickets guidance: part II-management.
Haffner D, Leifheit-Nestler M, Grund A, Schnabel D
Pediatric nephrology (Berlin, Germany) 2022; (37(10)):2289-2302 doi:10.1007/s00467-022-05505-5.
PMID: 35352187
This page explains HHRH and NPHLOP1 for educational purposes only and does not constitute medical advice. Do not start, stop, or change vitamin D or phosphate treatment without guidance from your prescriber or metabolic-bone team.